In corroboration of these molecular mechanisms, intermittent PTH exposure has been exploited therapeutically (PTH-analog administration in osteoporosis), having been documented to reduce osteocyte sclerostin expression, while simultaneously increasing bone mass [42]. The gene discussed is PTH; the disease is osteoporosis.